Date  |
|
| Apr 22, 2022 |
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022 |
| Feb 14, 2022 |
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results |
| Dec 22, 2021 |
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments |
| Oct 22, 2021 |
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility |
| Aug 16, 2021 |
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results |
| Jul 7, 2021 |
CEL-SCI Corporation Issues Letter to Shareholders |
| Jul 2, 2021 |
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available |
| Jun 30, 2021 |
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021 |
| Jun 28, 2021 |
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study |
| Jun 25, 2021 |
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting |